Evidence map›Paper›PMID 32798997›Full record

ArticleThe Journal of surgical research2020

Treatment Patterns and Distance to Treatment Facility for Soft Tissue Sarcoma of the Extremity.

Ambria S Moten, Margaret von Mehren, Sanjay Reddy, Krisha Howell, Elizabeth Handorf, Jeffrey M Farma

Abstract read
In one paragraph

Article in The Journal of surgical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ambria S MotenDepartment of Surgery, Temple University Hospital, Philadelphia, Pennsylvania. Electronic address: ambria.moten@tuhs.temple.edu.
Margaret von MehrenDepartment of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Sanjay ReddyDepartment of Surgery, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Krisha HowellDepartment of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Elizabeth HandorfDepartment of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Jeffrey M FarmaDepartment of Surgery, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
NCI NIH HHS P30 CA006927
6 · The paper itself

Abstract

backgroundThe impact that distance traveled to receive treatment has on treatments and outcomes among patients with soft tissue sarcoma (STS) of the extremity has yet to be thoroughly investigated.

methodsInformation on patients treated for STS of the extremity between 2006 and 2015 was obtained from the National Cancer Database. Patients were stratified into two groups based on median distance traveled to receive treatment. Chi-square tests assessed associations between categorical variables and distance to treatment. Kaplan-Meier survival estimates and Cox regression were used to estimate survival.

resultsThe sample included 21,763 patients. The mean age was 59.3 y, 54.6% were men, and 83.2% were white. The median distance traveled to the treating facility was 15.6 miles. Compared with patients who traveled <15 miles, those who traveled ≥15 miles were more likely to have undifferentiated rather than well-differentiated tumors (odds ratio [OR], 1.23; 95% confidence interval [95% CI], 1.10-1.37), and stage II rather than stage I disease (OR, 1.14; 95% CI, 1.04-1.24). They were also more likely to undergo limb-sparing resection (OR, 1.58; 95% CI, 1.39-1.79) or amputation (OR, 1.72; 95% CI, 1.44-2.07) rather than no surgery and less likely to have positive margins (OR, 0.86; 95% CI, 0.79-0.93). There was no difference in the risk of death between patients who traveled ≥15 miles and those who did not (hazard ratio, 1.00; 95% CI, 0.94-1.07).

conclusionsAlthough clinical characteristics and treatments may differ based on distance traveled, survival appears equivalent. Further research into reasons why greater distance traveled is associated with more advanced disease, but comparable survival is warranted.

Indexed as

AdultAgedAmputation, SurgicalDatabases, FactualExtremitiesFemaleGeographyHealth Services AccessibilityHumansKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedNeoplasm GradingNeoplasm StagingOrgan Sparing TreatmentsDistanceOutcomesSoft tissue sarcomaTreatment

Identifiers

PMID32798997
PMCPMC10034971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.